New York State Department of Financial Services adopts new market conduct regulations that will enable the regulatory oversight, transparency and accountability of PBMs operating in the state.
Featuring a sold-out exhibit floor with 1,821 exhibitors from 60 countries, the event welcomed 700 first-time exhibitors, underscoring its growing prominence in retail.
GlobalData warns that President-elect Trump's proposed tariffs could raise prices and disrupt access to 75% of U.S. medical devices.
Move would also ensure access to the medications for approximately 4 million adult Medicaid enrollees.
13 executives are stepping into new or expanded roles.
Seasonal shoppers focus on deals to make the most of every festive dollar this season.
The partnership will focus on supporting family caregivers with loved ones managing incontinence.
Nature’s Truth also remains the top brand in the independent pharmacy subcategories of single-letter vitamins; herbals and botanicals; specialty supplements; and mineral supplements, increasing its share in all four.
Chain Drug Review and Kearney hosted their third annual Health Equity Summit in Chicago, where a panel of experts discussed the prevalence of pharmacy deserts, affecting millions of Americans, and strategies to address these disparities.
BridgeBio Pharma has received FDA approval for a new drug for a rare heart disease after very promising trials.
Governor Kathy Hochul announced new regulations to govern Pharmacy Benefit Managers in New York. They aim to reduce prescription drug costs, increase transparency, and support small, independent pharmacies.
She succeeds Stuart Aitken, who will step down from his role as senior vice president and chief merchandising and marketing officer at the end of the year.
Johnson & Johnson has submitted an FDA application for the first subcutaneous IL-23 inhibitor for ulcerative colitis. This drug could offer patients a groundbreaking at-home treatment option.
